Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavoglurant (AFQ056) with L-dopa in Parkinson's Disease
NCT01092065Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2010
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) and levodopa-induced dyskinesia (LID) comparing AFQ056 + L-dopa with Placebo + L-dopa (2 arms). Primary endpoint: Change in total OFF time at 5 weeks. Started Mar 2010; status: completed.
02
Drugs
mavoglurant
03
Conditions
Parkinson's disease (PD)levodopa-induced dyskinesia (LID)
Beyond the preview
Go deeper on NCT01092065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01092065.